• Je něco špatně v tomto záznamu ?

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis

R. Keil, M. Wasserbauer, Z. Zádorová, J. Hajer, P. Drastich, P. Wohl, M. Beneš, M. Bojková, P. Svoboda, M. Konečný, P. Falt, T. Vaňásek, M. Pešta, F. Pešek, L. Bouchner, J. Koželuhová, A. Novotný, L. Bartůsková, J. Špičák,

. 2016 ; 51 (9) : 1062-8. [pub] 20160322

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031819

OBJECTIVE: The infliximab biosimilar CT-P13 (Remsima(®), Inflectra(®)) was approved in Europe for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from patients with rheumatic disease. Because there are limited published reports on clinical outcomes for IBD patients treated with CT-P13, we monitored responses to induction treatment with this biosimilar in patients with Crohn's disease (CD) or ulcerative colitis (UC) in centres across the Czech Republic. MATERIAL AND METHODS: Fifty-two patients with CD (n = 30) or UC (n = 22) were treated with 5 mg/kg CT-P13 for up to 14 weeks. Effectiveness of therapy was evaluated with the Crohn's Disease Activity Index (CDAI) or the Mayo Scoring System (MSS) in patients with CD or UC, respectively, before and after 14 weeks. Additional goals were to evaluate weight changes, serum C-reactive protein (CRP) levels, and complications/adverse events. RESULTS: In patients with CD, remission (CDAI <150) was achieved in 50.0% of cases, and partial response (≥70-point decrease in CDAI score from baseline) in the remaining 50.0%. In patients with UC, remission (total score on partial Mayo index ≤2 points) was achieved in 40.9% of cases, partial response (≥2-point decrease in partial Mayo score from baseline) in 54.5%, and no response in 4.5%. There were statistically significant improvements in CDAI, MSS and CRP serum levels after 14 weeks of therapy, and body weight increased. Four adverse events were identified (n = 1 each): lower-extremity phlebothrombosis, herpes labialis, pneumonia and allergic reaction. CONCLUSIONS: This prospective observational study provides evidence of the effectiveness of CT-P13 in IBD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031819
003      
CZ-PrNML
005      
20171103102813.0
007      
ta
008      
171025s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/00365521.2016.1149883 $2 doi
035    __
$a (PubMed)27002981
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Keil, Radan $u a Department of Internal Medicine, 2nd Faculty of Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic ;
245    10
$a Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis / $c R. Keil, M. Wasserbauer, Z. Zádorová, J. Hajer, P. Drastich, P. Wohl, M. Beneš, M. Bojková, P. Svoboda, M. Konečný, P. Falt, T. Vaňásek, M. Pešta, F. Pešek, L. Bouchner, J. Koželuhová, A. Novotný, L. Bartůsková, J. Špičák,
520    9_
$a OBJECTIVE: The infliximab biosimilar CT-P13 (Remsima(®), Inflectra(®)) was approved in Europe for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from patients with rheumatic disease. Because there are limited published reports on clinical outcomes for IBD patients treated with CT-P13, we monitored responses to induction treatment with this biosimilar in patients with Crohn's disease (CD) or ulcerative colitis (UC) in centres across the Czech Republic. MATERIAL AND METHODS: Fifty-two patients with CD (n = 30) or UC (n = 22) were treated with 5 mg/kg CT-P13 for up to 14 weeks. Effectiveness of therapy was evaluated with the Crohn's Disease Activity Index (CDAI) or the Mayo Scoring System (MSS) in patients with CD or UC, respectively, before and after 14 weeks. Additional goals were to evaluate weight changes, serum C-reactive protein (CRP) levels, and complications/adverse events. RESULTS: In patients with CD, remission (CDAI <150) was achieved in 50.0% of cases, and partial response (≥70-point decrease in CDAI score from baseline) in the remaining 50.0%. In patients with UC, remission (total score on partial Mayo index ≤2 points) was achieved in 40.9% of cases, partial response (≥2-point decrease in partial Mayo score from baseline) in 54.5%, and no response in 4.5%. There were statistically significant improvements in CDAI, MSS and CRP serum levels after 14 weeks of therapy, and body weight increased. Four adverse events were identified (n = 1 each): lower-extremity phlebothrombosis, herpes labialis, pneumonia and allergic reaction. CONCLUSIONS: This prospective observational study provides evidence of the effectiveness of CT-P13 in IBD.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
650    _2
$a biosimilární léčivé přípravky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D059451
650    _2
$a C-reaktivní protein $x analýza $7 D002097
650    _2
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    _2
$a Crohnova nemoc $x farmakoterapie $7 D003424
650    _2
$a Česká republika $7 D018153
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální látky $x aplikace a dávkování $x škodlivé účinky $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a infliximab $x aplikace a dávkování $x škodlivé účinky $7 D000069285
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a indukce remise $7 D012074
650    _2
$a sexuální faktory $7 D012737
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Wasserbauer, Martin $u a Department of Internal Medicine, 2nd Faculty of Medicine , Charles University in Prague and Motol University Hospital , Prague , Czech Republic ;
700    1_
$a Zádorová, Zdena $u b 2nd Department of Internal Medicine, 3rd Faculty of Medicine , Charles University in Prague, FNKV , Prague , Czech Republic ;
700    1_
$a Hajer, Jan $u b 2nd Department of Internal Medicine, 3rd Faculty of Medicine , Charles University in Prague, FNKV , Prague , Czech Republic ;
700    1_
$a Drastich, Pavel $u c Department of Hepatogastroenterology , Institute for Clinical and Experimental Medicine , Prague , Czech Republic ;
700    1_
$a Wohl, Pavel $u c Department of Hepatogastroenterology , Institute for Clinical and Experimental Medicine , Prague , Czech Republic ;
700    1_
$a Beneš, Marek $u c Department of Hepatogastroenterology , Institute for Clinical and Experimental Medicine , Prague , Czech Republic ;
700    1_
$a Bojková, Martina $u d Clinic of Internal Medicine, University Hospital Ostrava , Ostrava , Czech Republic ;
700    1_
$a Svoboda, Pavel $u d Clinic of Internal Medicine, University Hospital Ostrava , Ostrava , Czech Republic ;
700    1_
$a Konečný, Michal $u e 2nd Department of Internal Medicine , University Hospital Olomouc , Olomouc , Czech Republic ;
700    1_
$a Falt, Přemysl $u f Digestive Diseases Center, Vítkovice Hospital , Ostrava , Czech Republic ;
700    1_
$a Vaňásek, Tomáš $u g 2nd Department of Internal Medicine-Gastroenterology , University Hospital Hradec Králové, Hradec Králové , Czech Republic ;
700    1_
$a Pešta, Martin $u h Department of Internal Medicine , Hospital Na Bulovce , Prague , Czech Republic ;
700    1_
$a Pešek, František $u i 2nd Department of Internal Medicine , University Hospital Plzeň-Bory , Plzeň, Czech Republic ;
700    1_
$a Bouchner, Luděk $u i 2nd Department of Internal Medicine , University Hospital Plzeň-Bory , Plzeň, Czech Republic ;
700    1_
$a Koželuhová, Jana $u j 4th Department of Internal Medicine - Clinic of Gastroenterology and Hepatology , The General University Hospital in Prague, 1st Medical Faculty, Charles University in Prague , Prague , Czech Republic ;
700    1_
$a Novotný, Aleš $u j 4th Department of Internal Medicine - Clinic of Gastroenterology and Hepatology , The General University Hospital in Prague, 1st Medical Faculty, Charles University in Prague , Prague , Czech Republic ;
700    1_
$a Bartůsková, Lucie $u k Department of Economic and Social Policy , University of Economics , Prague , Czech Republic.
700    1_
$a Špičák, Julius $u c Department of Hepatogastroenterology , Institute for Clinical and Experimental Medicine , Prague , Czech Republic ;
773    0_
$w MED00010598 $t Scandinavian journal of gastroenterology $x 1502-7708 $g Roč. 51, č. 9 (2016), s. 1062-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27002981 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171103102907 $b ABA008
999    __
$a ok $b bmc $g 1255412 $s 992846
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 51 $c 9 $d 1062-8 $e 20160322 $i 1502-7708 $m Scandinavian journal of gastroenterology $n Scand J Gastroenterol $x MED00010598
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace